Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma.

@article{Cuzzocrea2006GlycogenSK,
  title={Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma.},
  author={Salvatore Cuzzocrea and T. Genovese and Emanuela Mazzon and Concetta Crisafulli and Rosanna di Paola and Carmelo Mui{\`a} and Marika Collin and Emanuela Esposito and Placido Bramanti and Christoph Thiemermann},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2006},
  volume={318 1},
  pages={79-89}
}
Glycogen synthase kinase-3 (GSK-3) has recently been identified as an ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and plays an important role in the pathophysiology of a number of diseases. The aim of this study was to investigate the effects of GSK-3beta inhibition on the degree of experimental spinal cord trauma induced by the application of vascular clips (force of 24 g) to the dura via a four-level T5-T8 laminectomy. Spinal cord injury… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 21 extracted citations

Similar Papers

Loading similar papers…